title: Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice.
abstract: OBJECTIVE
  Human prostate cancer is variably lethal, shows heterogeneous progression, and exhibits a spectrum of histopathology. Traditional rodent models of prostate cancer lack these characteristics. An alternative, autochthonous model of prostate cancer consists of transgenic mice which develop prostate cancer due to prostatic expression of SV40 T antigen. Lethal progression of such cancers in individual mice has not been previously characterized. Studies were undertaken to characterize the longitudinal progression of prostate cancers in these transgenic mice.
  
  
  METHODS
  A prospective longitudinal cohort study was undertaken to characterize prostate cancer volume, progression, lethality, and histological heterogeneity in a transgenic mouse model of prostatic adenocarcinoma. Fifty-one transgenic mice were followed prospectively to determine the age at onset of palpable tumor and age at cancer-related death. Tumor volume was followed longitudinally by magnetic resonance imaging (MRI) in a subset of these mice and lethal cancers were evaluated by histopathology.
  
  
  RESULTS
  Primary tumors became palpable at 10-38 weeks of age. Palpable tumors always preceded lethal progression. Cancer death followed 2-9 weeks later, and age at cancer death varied from 24 to 39 weeks of age. The histopathological changes were heterogeneous. Primary tumors were detectable by MRI before they became detectable by palpation. MRI showed that, analogous to human prostate cancers, volume of early stage primary tumors did not necessarily predict age at cancer death.
  
  
  CONCLUSIONS
  Prostate cancer in transgenic mice mimics heterogeneic tumor progression in human prostate cancer, providing a uniquely relevant pre-clinical model. Tumor detection by MRI and palpation are valid surrogate measures of tumor progression in this model.
authors.affiliation: Department of Surgery/Urology, University of Michigan School of Medicine, Ann Arbor Veterans Administration Medical Center, USA.
authors.forename: C X
authors.initials: CX
authors.lastname: Hsu
authors.forename: B D
authors.initials: BD
authors.lastname: Ross
authors.forename: C E
authors.initials: CE
authors.lastname: Chrisp
authors.forename: S Z
authors.initials: SZ
authors.lastname: Derrow
authors.forename: L G
authors.initials: LG
authors.lastname: Charles
authors.forename: K J
authors.initials: KJ
authors.lastname: Pienta
authors.forename: N M
authors.initials: NM
authors.lastname: Greenberg
authors.forename: Z
authors.initials: Z
authors.lastname: Zeng
authors.forename: M G
authors.initials: MG
authors.lastname: Sanda
mesh_terms: D000818:Animals; D018450:Disease Progression; D008137:Longitudinal Studies; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D011471:Prostatic Neoplasms / Q000473:pathology*